All companies
Illumina, Inc. logo

What smart money is saying about Illumina, Inc.United States flag

ILMN · Healthcare · Medical - Diagnostics & Research · Market cap $20.53B

3 funds in our archive have pitched Illumina, Inc. — most recently Baron Global Advantage Fund in June 2025.

Company profile

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.

Get an email when a fund writes about it

Summarize with Warren AI
3
Reported positions
0
Bought
0
Sold
6
Letters

Position history

Between Q4 2024 and Q2 2026, 3 fund letters reported a position in Illumina, Inc., with no move described.

Fund letters reporting a position in Illumina, Inc., by quarter
QuarterLettersBoughtSoldTheses
Q2 20261000
Q1 20262000
Q2 20250001
Q1 20250001
Q4 20240001

Fund activity · 3 positions

  • HoldsHardman Johnston Global Advisors Large Cap Equity
    June 2026
    In the quarter, performance was driven by gains in Illumina, Inc., SharkNinja, Inc., and Vertiv Holdings Co.
    Read the letterIllumina, Inc.
  • HoldsHardman Johnston Large Cap Equity
    March 2026
    Edwards Lifesciences Corp. United States 2.7 Health Care Equipment & Supplies Illumina, Inc. United States 2.5 Life Sciences Tools & Services
    Read the letterIllumina, Inc.
  • HoldsHardman Johnston Select Equity
    March 2026
    Illumina, Inc. United States 2.0 Life Sciences Tools & Services
    Read the letterIllumina, Inc.

Fund coverage · 3 theses

  • Baron Global Advantage Fund
    June 2025

    Illumina, Inc. is a leading DNA sequencing platform with strong long-term growth potential despite recent pressures, driven by its competitive advantages in the expanding $40 billion clinical diagnostics market.

    Read the full thesis
  • Diamond Hill Small Mid Cap Fund
    March 2025

    Illumina is a leader in genetic sequencing with an 80% market share, strong fundamentals, and promising long-term growth potential despite recent share price pressures.

    Read the full thesis
  • Brown Advisory
    December 2024

    Illumina is a leading U.S. life science and diagnostics company that has revolutionized gene sequencing, significantly reducing costs and driving growth in personalized medicine, while maintaining a dominant market share and high customer switching costs.

    Read the full thesis

Read every full thesis on Illumina, Inc.

Unlock all 3 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.

View plans
Share this ledger